Compare ETB & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Tax-Managed Buy-Write Income Fund Eaton Vance Tax-Managed Buy-Write Income Fund of Beneficial Interest
Current Price
| Metric | ETB | CYRX |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.2M | 438.7M |
| IPO Year | N/A | N/A |
| Metric | ETB | CYRX |
|---|---|---|
| Price | $15.22 | $9.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.83 |
| AVG Volume (30 Days) | 71.8K | ★ 574.8K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 8.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.27 |
| Revenue | N/A | ★ $243,795,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.20 |
| P/E Ratio | ★ N/A | $7.76 |
| Revenue Growth | N/A | ★ 41.27 |
| 52 Week Low | $11.59 | $4.58 |
| 52 Week High | $14.08 | $11.44 |
| Indicator | ETB | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 57.01 |
| Support Level | $15.17 | $9.08 |
| Resistance Level | $15.37 | $9.72 |
| Average True Range (ATR) | 0.19 | 0.43 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 81.32 | 86.40 |
Eaton Vance Tax-Managed Buy-Write Income Fund is a United States-based diversified closed ended management investment company. The fund's investment objective is to provide current income and gains, with a secondary objective of capital appreciation. It invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of aerospace and defense, banks, biotechnology, chemicals, consumer finance, industrial conglomerates, and others.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.